Advertisement
U.S. markets open in 6 hours 59 minutes

Inozyme Pharma, Inc. (INZY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.54-0.10 (-1.77%)
At close: 04:00PM EST
5.27 -0.27 (-4.87%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close5.64
Open5.65
Bid0.00 x 800
Ask0.00 x 800
Day's Range5.45 - 5.70
52 Week Range2.51 - 7.33
Volume395,866
Avg. Volume431,763
Market Cap342.154M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-1.44
Earnings DateMar 20, 2024 - Mar 25, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for INZY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Inozyme Pharma, Inc.
    Daily – Vickers Top Buyers & Sellers for 02/02/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 years agoArgus Research
View more
  • GlobeNewswire

    Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to four new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as inducement material to the new employees entering i

  • Simply Wall St.

    Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)

    Key Insights Given the large stake in the stock by institutions, Inozyme Pharma's stock price might be vulnerable to...

  • GlobeNewswire

    Inozyme Pharma to Participate in Upcoming Investor Conferences

    BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate at the following investor conferences: The Jefferies London Healthcare Conference. The presentation will